Drug Approval | December 27, 2023
Eugia Pharma Specialities receives USFDA final approval for Posaconazole Injection
The product is expected to be launched in December 2023
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The product will be manufactured at Lupin's Pithampur facility in India
Receives registration of Valganciclovir powder for oral solution in Germany
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Subscribe To Our Newsletter & Stay Updated
